{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
{{--

GLIDE Study - Research and Insights on GI motiLity Disorders In Diabetic PatiEnts

--}}
Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif @if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

  1. What percentage of your diabetic patients are on combination drug therapy? *

  2. Which combination therapy do you most commonly prescribe? *
  3. What is the primary factor influencing your choice of combination therapy? *

  4. How often do you monitor HbA1c levels in your diabetic patients? *

  5. What percentage of your patients achieve target HbA1c levels with combination therapy? *

  6. Which factor do you believe most contributes to poor glycemic control in your patients? *
  7. How often do you encounter side effects from combination therapy in your patients? *

  8. Which side effect is most commonly reported by your patients on combination therapy? *

  9. How do you manage patients who experience side effects from combination therapy? *

  10. What percentage of your diabetic patients are also diagnosed with hypertension? *

  11. How often do you prescribe lifestyle modifications along with combination therapy? *

  12. Which lifestyle modification do you emphasize the most? *
  13. How effective do you find lifestyle modifications in managing diabetes? *

  14. What is the most common barrier to effective diabetes management in your patients? *

  15. How often do you use patient education materials in your practice? *

  16. Which type of patient education material do you find most effective? *

  17. How do you rate the availability of diabetes management resources in your region? *

  18. What percentage of your patients use insulin as part of their diabetes management? *

  19. How often do you encounter patients with diabetes-related complications? *

  20. Which diabetes-related complication do you see most often? *

  21. How do you address diabetes-related complications in your practice? *

  22. What is your primary source of information on diabetes management? *

  23. How confident are you in managing diabetes with combination therapy? *

  24. What additional support would help you in managing diabetes more effectively? *

  25. In your opinion, what are the most promising new treatment options for diabetes that have emerged in the last few years? *
  26. How do you foresee the role of continuous glucose monitoring evolving in diabetes management over the next 5-10 years? *
  27. What are the biggest challenges you face when implementing newer diabetes management technologies in your practice? *
  28. How do you think patient adherence to newer diabetes treatments (e.g., GLP-1 receptor agonists, SGLT2 inhibitors) compares to more traditional treatments? *
  29. In your experience, how effective are recent advancements in diabetes medications in achieving long-term glycemic control for your patients? *
  30. What is your perspective on the growing trend of personalized medicine in diabetes treatment? How do you incorporate this into your practice? *
  31. Can you discuss any potential risks or downsides of newer diabetes management therapies, such as their long-term safety or side effect profiles?*
  32. What role do you see lifestyle interventions (e.g., diet, exercise) playing alongside newer pharmaceutical treatments in diabetes management? *
  33. With the increasing focus on managing comorbidities in diabetes patients (e.g., cardiovascular disease, kidney disease), how do you approach integrated care for these patients? *
  34. Which of the following factors most often limits your choice of combination therapy for Type 2 diabetes patients with comorbidities? *
  35. Which class of drugs do you most commonly combine with metformin for Type 2 diabetes management in patients with comorbidities? *

  36. How often do you consider the patient’s other medications (for comorbidities) when selecting a combination therapy for diabetes? *

  37. How important is it to you that a combination therapy has proven cardiovascular benefits in diabetes patients with comorbidities? *

  38. When prescribing combination therapy, do you consider the potential for drug-drug interactions with other medications the patient is taking? *

  39. How often do you adjust combination therapy based on a patient’s specific comorbid condition (e.g., renal or hepatic impairment)? *

  40. Do you typically choose drugs that are effective in reducing both blood glucose and weight for patients with Type 2 diabetes and obesity? *

  41. How often do you consider patient education on the benefits of combination therapy when prescribing? *

  42. When prescribing combination therapy, do you prioritize drugs that have a once- daily dosing regimen? *

  43. What is your take on GLP1 RA and how often do you prescribe them? *
  44. Do you ever consider patient preferences when prescribing combination therapy for Type 2 diabetes with comorbidities? *

  45. What percentage of your patients with cardio-kidney-metabolic syndrome are on combination therapy? *

  46. Which combination therapy do you most commonly prescribe for cardio-kidney- metabolic syndrome? *
  47. How often do you monitor renal function in patients with cardio-kidney-metabolic syndrome? *

  48. What is the primary factor influencing your choice of treatment for cardio-kidney- metabolic syndrome? *

  49. How effective do you find lifestyle modifications in managing cardio-kidney- metabolic syndrome? *

  50. What additional support would help you in managing patients with cardio-kidney- metabolic syndrome more effectively? *